BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

586 related articles for article (PubMed ID: 20870345)

  • 1. Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes.
    Sasso M; Beaugrand M; de Ledinghen V; Douvin C; Marcellin P; Poupon R; Sandrin L; Miette V
    Ultrasound Med Biol; 2010 Nov; 36(11):1825-35. PubMed ID: 20870345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver Steatosis Assessed by Controlled Attenuation Parameter (CAP) Measured with the XL Probe of the FibroScan: A Pilot Study Assessing Diagnostic Accuracy.
    Sasso M; Audière S; Kemgang A; Gaouar F; Corpechot C; Chazouillères O; Fournier C; Golsztejn O; Prince S; Menu Y; Sandrin L; Miette V
    Ultrasound Med Biol; 2016 Jan; 42(1):92-103. PubMed ID: 26386476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography.
    Myers RP; Pollett A; Kirsch R; Pomier-Layrargues G; Beaton M; Levstik M; Duarte-Rojo A; Wong D; Crotty P; Elkashab M
    Liver Int; 2012 Jul; 32(6):902-10. PubMed ID: 22435761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How good is controlled attenuation parameter and fatty liver index for assessing liver steatosis in general population: correlation with ultrasound.
    Carvalhana S; Leitão J; Alves AC; Bourbon M; Cortez-Pinto H
    Liver Int; 2014 Jul; 34(6):e111-7. PubMed ID: 24034415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic accuracy of controlled attenuation parameter measured by transient elastography for the non-invasive assessment of liver steatosis: a prospective study.
    Lupșor-Platon M; Feier D; Stefănescu H; Tamas A; Botan E; Sparchez Z; Maniu A; Badea R
    J Gastrointestin Liver Dis; 2015 Mar; 24(1):35-42. PubMed ID: 25822432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography.
    de Lédinghen V; Vergniol J; Foucher J; Merrouche W; le Bail B
    Liver Int; 2012 Jul; 32(6):911-8. PubMed ID: 22672642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis: does etiology affect performance?
    Kumar M; Rastogi A; Singh T; Behari C; Gupta E; Garg H; Kumar R; Bhatia V; Sarin SK
    J Gastroenterol Hepatol; 2013 Jul; 28(7):1194-201. PubMed ID: 23425053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease.
    Chan WK; Nik Mustapha NR; Mahadeva S
    J Gastroenterol Hepatol; 2014; 29(7):1470-6. PubMed ID: 24548002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical usefulness of controlled attenuation parameter to screen hepatic steatosis for potential donor of living donor liver transplant.
    Hong YM; Yoon KT; Cho M; Chu CW; Rhu JH; Yang KH; Lee JW
    Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):805-810. PubMed ID: 28379854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Noninvasive detection of hepatic steatosis in patients without ultrasonographic evidence of fatty liver using the controlled attenuation parameter evaluated with transient elastography.
    Yilmaz Y; Ergelen R; Akin H; Imeryuz N
    Eur J Gastroenterol Hepatol; 2013 Nov; 25(11):1330-4. PubMed ID: 23660937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Controlled attenuation parameter for steatosis grading in chronic hepatitis C compared with digital morphometric analysis of liver biopsy: impact of individual elastography measurement quality.
    Mendes LC; Ferreira PA; Miotto N; Zanaga L; Lazarini MS; Gonçales ESL; Pedro MN; Gonçales FL; Stucchi RSB; Vigani AG
    Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):959-966. PubMed ID: 29727388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population.
    Chon YE; Jung KS; Kim SU; Park JY; Park YN; Kim DY; Ahn SH; Chon CY; Lee HW; Park Y; Han KH
    Liver Int; 2014 Jan; 34(1):102-9. PubMed ID: 24028214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controlled attenuation parameter for noninvasive assessment of hepatic steatosis using Fibroscan®: validation in chronic hepatitis B.
    Mi YQ; Shi QY; Xu L; Shi RF; Liu YG; Li P; Shen F; Lu W; Fan JG
    Dig Dis Sci; 2015 Jan; 60(1):243-51. PubMed ID: 25194851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of hepatic steatosis using the controlled attenuation parameter: a comparative study with liver biopsy.
    Yilmaz Y; Yesil A; Gerin F; Ergelen R; Akin H; Celikel ÇA; Imeryuz N
    Scand J Gastroenterol; 2014 May; 49(5):611-6. PubMed ID: 24611771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The controlled attenuation parameter (CAP): a novel tool for the non-invasive evaluation of steatosis using Fibroscan.
    Sasso M; Miette V; Sandrin L; Beaugrand M
    Clin Res Hepatol Gastroenterol; 2012 Feb; 36(1):13-20. PubMed ID: 21920839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations.
    de Lédinghen V; Vergniol J; Capdepont M; Chermak F; Hiriart JB; Cassinotto C; Merrouche W; Foucher J; Brigitte le B
    J Hepatol; 2014 May; 60(5):1026-31. PubMed ID: 24378529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease.
    de Lédinghen V; Wong GL; Vergniol J; Chan HL; Hiriart JB; Chan AW; Chermak F; Choi PC; Foucher J; Chan CK; Merrouche W; Chim AM; Le Bail B; Wong VW
    J Gastroenterol Hepatol; 2016 Apr; 31(4):848-55. PubMed ID: 26514665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan(®): validation in chronic hepatitis C.
    Sasso M; Tengher-Barna I; Ziol M; Miette V; Fournier C; Sandrin L; Poupon R; Cardoso AC; Marcellin P; Douvin C; de Ledinghen V; Trinchet JC; Beaugrand M
    J Viral Hepat; 2012 Apr; 19(4):244-53. PubMed ID: 22404722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controlled attenuation parameter for the detection of steatosis severity in chronic liver disease: a meta-analysis of diagnostic accuracy.
    Shi KQ; Tang JZ; Zhu XL; Ying L; Li DW; Gao J; Fang YX; Li GL; Song YJ; Deng ZJ; Wu JM; Tang KF
    J Gastroenterol Hepatol; 2014 Jun; 29(6):1149-58. PubMed ID: 24476011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of hepatic steatosis index, controlled attenuation parameter and ultrasound as noninvasive diagnostic tools for steatosis in chronic hepatitis B.
    Xu L; Lu W; Li P; Shen F; Mi YQ; Fan JG
    Dig Liver Dis; 2017 Aug; 49(8):910-917. PubMed ID: 28433586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.